Johnson & Johnson (JNJ): Dividend Yield, Returns & Analysis

Johnson & Johnson (NYSE: JNJ) is one of the longest-running Dividend Kings in the United States, with over 60 consecutive years of annual dividend increases. Few companies anywhere in the world can match this track record, which reflects not only financial strength but remarkable business durability across decades of economic cycles, product challenges, and industry disruptions. For dividend investors focused on long-term income reliability, Johnson & Johnson has historically been considered one of the highest-quality holdings available.

The company restructured significantly in 2023 with the spin-off of its consumer health division — which included brands such as Tylenol, Band-Aid, Listerine, and Neutrogena — into a separate publicly traded company called Kenvue. The remaining JNJ business now focuses entirely on pharmaceutical and medical device operations, including blockbuster drugs in immunology, oncology, and neuroscience. This strategic repositioning was designed to create a more focused, higher-margin business capable of sustaining strong dividend growth even as individual drug patents expire.

Johnson & Johnson holds one of only a handful of AAA credit ratings among US corporations, reflecting its exceptional balance sheet strength. This financial position means the company has the capacity to sustain its dividend even in severe economic downturns. For dividend investors, JNJ represents a core holding that prioritises safety and consistency over high current yield — typically in the 2.5–3.5% range — making it particularly suitable as a defensive anchor in a diversified income portfolio.